News

Video: Jenniffer Dietrich, Challenge Facility for Civil Society

Jenniffer Dietrich is Technical Officer at the Challenge Facility for Civil Society of the Stop TB Partnership.

Communities are coming together to advocate and improve their own access to health services and increasingly organizing to plan and deliver effective healthcare on a large scale. Though it will never replace or match the national delivery of health, it can and does make a considerable contribution acting synergistically to improve access for marginalized groups, maintaining contact and referral to health services and ultimately creating a highly effective network of health interventions and community health systems.

The Stop TB Partnership’s Challenge Facility for Civil Society (CFCS) targets grass-roots and community-based civil society organizations that seek to help shape policy at local levels by giving a voice to people living with TB and those involved in its prevention, treatment and care. Proposals are selected by an independent selection committee composed of a maximum of 10 representatives from the community affected by TB, NGOs from developing and developed countries, NTP managers, multilateral or technical agencies.

More News
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...